Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients

Eisai Korea Inc.40 enrolled

Overview

This study will be conducted to observe the difference in microbiome composition between healthy participants and inflammatory bowel disease (IBD) participants with no anti-tumor necrosis factor (anti-TNF) treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Inflammatory Bowel Disease

Eligibility

Sex: ALLMin age: 19 YearsHealthy volunteers:

Medical Language ↔ Plain English

1. Inclusion/ Exclusion Criteria: 1. Inclusion Criteria For Inflammatory Bowel Disease (IBD) participants: * Male or female, age ≥ 19 years at the time of informed consent * Confirmed diagnosis of IBD * Participants who are naïve to anti-tumour necrosis factor (anti-TNF) 2. Exclusion Criteria for IBD participants: * Contraindication to anti-TNF including active tuberculosis (TB), sepsis, or other severe opportunistic infection, etc. 2. Inclusion/ Exclusion Criteria: 1. Inclusion Criteria for non-IBD participants: * Participants who have not been diagnosed with IBD * Participants who don't have any other intestinal disease except IBD * Participants who are naïve to anti-TNF 2. Exclusion Criteria for non-IBD participants: * Participants who have been on medication to treat underlying disease for the previous 3 months

Locations (3)

Eisai Trial Site # 1

Seoul, South Korea

Eisai Trial Site # 2

Seoul, South Korea

Eisai Trial Site # 3

Seoul, South Korea

Outcomes

Primary Outcomes

Change in the composition of the microbiome after anti-tumour necrosis factor (anti-TNF) treatment for inflammatory bowel disease (IBD) at Month 3

Microbiome is the microorganisms in a particular environment (including the body or a part of the body). Changes in the microbiome in fecal, blood, saliva, and urine samples before and after anti-TNF treatment will be assessed.

Time frame: Month 3

Secondary Outcomes

The difference in the composition of the microbiome at baseline between IBD participants and non-IBD participants

Time frame: Baseline

Disease activity will be assessed by Crohn's Disease Activity Index (CDAI) or Mayo score for ulcerative colitis (UC)

Disease activity will be assessed by CDAI to quantify the symptoms.

Time frame: Up to 3 months

Correlation in the composition of the microbiome at baseline and disease activity will be assessed as measured by CDAI or Mayo score at Month 3

The composition of the microbiome at baseline will be correlated to disease activity which is assessed as measured by CDAI or Mayo score at Month 3.

Time frame: Baseline; Month 3

Change from baseline in calprotectin at Month 3

Fecal calprotectin can indicate inflammation in the intestines.

Time frame: Baseline; Month 3

Number of participants with abnormal, clinically significant vital signs

Clinical significance will be determined by the investigator.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.